Financhill
Sell
14

GALT Quote, Financials, Valuation and Earnings

Last price:
$0.89
Seasonality move :
33.46%
Day range:
$0.73 - $1.50
52-week range:
$0.73 - $4.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
9.2M
Avg. volume:
778.9K
1-year change:
-39.77%
Market cap:
$64.6M
Revenue:
--
EPS (TTM):
-$0.73

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GALT
Galectin Therapeutics
-- -- -- -- --
AVXL
Anavex Life Sciences
-- -$0.17 -- -30.77% --
OGEN
Oragenics
-- -- -- -- --
PHAT
Phathom Pharmaceuticals
$12.4M -$1.47 3678.74% -26.9% $22.00
SLS
SELLAS Life Sciences Group
-- -$0.13 -- -57.33% --
TCRT
Alaunos Therapeutics
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GALT
Galectin Therapeutics
$1.03 -- $64.6M -- $0.00 0% --
AVXL
Anavex Life Sciences
$8.63 -- $731.8M -- $0.00 0% --
OGEN
Oragenics
$0.36 -- $4.3M -- $0.00 0% 1.40x
PHAT
Phathom Pharmaceuticals
$7.45 $22.00 $509.4M -- $0.00 0% 16.94x
SLS
SELLAS Life Sciences Group
$0.90 -- $63.4M -- $0.00 0% --
TCRT
Alaunos Therapeutics
$2.03 -- $3.2M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GALT
Galectin Therapeutics
-- -3.116 -- --
AVXL
Anavex Life Sciences
-- 3.153 -- --
OGEN
Oragenics
-- 5.927 -- --
PHAT
Phathom Pharmaceuticals
-1543.79% 2.279 14.23% 5.45x
SLS
SELLAS Life Sciences Group
-- 0.853 -- --
TCRT
Alaunos Therapeutics
-- 2.640 -- 2.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GALT
Galectin Therapeutics
-- -$9.1M -- -- -- -$8.5M
AVXL
Anavex Life Sciences
-- -$14.7M -- -- -- -$5.2M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PHAT
Phathom Pharmaceuticals
$14M -$70.8M -- -- -410.31% -$63.6M
SLS
SELLAS Life Sciences Group
-- -$7.3M -- -- -- -$7.8M
TCRT
Alaunos Therapeutics
-- -$1.2M -189.69% -189.69% -28225% -$781K

Galectin Therapeutics vs. Competitors

  • Which has Higher Returns GALT or AVXL?

    Anavex Life Sciences has a net margin of -- compared to Galectin Therapeutics's net margin of --. Galectin Therapeutics's return on equity of -- beat Anavex Life Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GALT
    Galectin Therapeutics
    -- -$0.18 --
    AVXL
    Anavex Life Sciences
    -- -$0.14 --
  • What do Analysts Say About GALT or AVXL?

    Galectin Therapeutics has a consensus price target of --, signalling upside risk potential of 967.96%. On the other hand Anavex Life Sciences has an analysts' consensus of -- which suggests that it could grow by 311.04%. Given that Galectin Therapeutics has higher upside potential than Anavex Life Sciences, analysts believe Galectin Therapeutics is more attractive than Anavex Life Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    GALT
    Galectin Therapeutics
    0 0 0
    AVXL
    Anavex Life Sciences
    0 0 0
  • Is GALT or AVXL More Risky?

    Galectin Therapeutics has a beta of 0.689, which suggesting that the stock is 31.07% less volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.729, suggesting its less volatile than the S&P 500 by 27.09%.

  • Which is a Better Dividend Stock GALT or AVXL?

    Galectin Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GALT or AVXL?

    Galectin Therapeutics quarterly revenues are --, which are smaller than Anavex Life Sciences quarterly revenues of --. Galectin Therapeutics's net income of -$11.2M is higher than Anavex Life Sciences's net income of -$12.2M. Notably, Galectin Therapeutics's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics is -- versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
    AVXL
    Anavex Life Sciences
    -- -- -- -$12.2M
  • Which has Higher Returns GALT or OGEN?

    Oragenics has a net margin of -- compared to Galectin Therapeutics's net margin of --. Galectin Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GALT
    Galectin Therapeutics
    -- -$0.18 --
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About GALT or OGEN?

    Galectin Therapeutics has a consensus price target of --, signalling upside risk potential of 967.96%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 25237.83%. Given that Oragenics has higher upside potential than Galectin Therapeutics, analysts believe Oragenics is more attractive than Galectin Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GALT
    Galectin Therapeutics
    0 0 0
    OGEN
    Oragenics
    0 0 0
  • Is GALT or OGEN More Risky?

    Galectin Therapeutics has a beta of 0.689, which suggesting that the stock is 31.07% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.

  • Which is a Better Dividend Stock GALT or OGEN?

    Galectin Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GALT or OGEN?

    Galectin Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Galectin Therapeutics's net income of -$11.2M is lower than Oragenics's net income of -$2.5M. Notably, Galectin Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics is -- versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
    OGEN
    Oragenics
    1.40x -- -- -$2.5M
  • Which has Higher Returns GALT or PHAT?

    Phathom Pharmaceuticals has a net margin of -- compared to Galectin Therapeutics's net margin of -523.34%. Galectin Therapeutics's return on equity of -- beat Phathom Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GALT
    Galectin Therapeutics
    -- -$0.18 --
    PHAT
    Phathom Pharmaceuticals
    85.59% -$1.32 -$11.4M
  • What do Analysts Say About GALT or PHAT?

    Galectin Therapeutics has a consensus price target of --, signalling upside risk potential of 967.96%. On the other hand Phathom Pharmaceuticals has an analysts' consensus of $22.00 which suggests that it could grow by 233.65%. Given that Galectin Therapeutics has higher upside potential than Phathom Pharmaceuticals, analysts believe Galectin Therapeutics is more attractive than Phathom Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    GALT
    Galectin Therapeutics
    0 0 0
    PHAT
    Phathom Pharmaceuticals
    5 1 0
  • Is GALT or PHAT More Risky?

    Galectin Therapeutics has a beta of 0.689, which suggesting that the stock is 31.07% less volatile than S&P 500. In comparison Phathom Pharmaceuticals has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.812%.

  • Which is a Better Dividend Stock GALT or PHAT?

    Galectin Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics pays -- of its earnings as a dividend. Phathom Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GALT or PHAT?

    Galectin Therapeutics quarterly revenues are --, which are smaller than Phathom Pharmaceuticals quarterly revenues of $16.4M. Galectin Therapeutics's net income of -$11.2M is higher than Phathom Pharmaceuticals's net income of -$85.6M. Notably, Galectin Therapeutics's price-to-earnings ratio is -- while Phathom Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics is -- versus 16.94x for Phathom Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
    PHAT
    Phathom Pharmaceuticals
    16.94x -- $16.4M -$85.6M
  • Which has Higher Returns GALT or SLS?

    SELLAS Life Sciences Group has a net margin of -- compared to Galectin Therapeutics's net margin of --. Galectin Therapeutics's return on equity of -- beat SELLAS Life Sciences Group's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GALT
    Galectin Therapeutics
    -- -$0.18 --
    SLS
    SELLAS Life Sciences Group
    -- -$0.10 --
  • What do Analysts Say About GALT or SLS?

    Galectin Therapeutics has a consensus price target of --, signalling upside risk potential of 967.96%. On the other hand SELLAS Life Sciences Group has an analysts' consensus of -- which suggests that it could grow by 547.72%. Given that Galectin Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Galectin Therapeutics is more attractive than SELLAS Life Sciences Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    GALT
    Galectin Therapeutics
    0 0 0
    SLS
    SELLAS Life Sciences Group
    0 0 0
  • Is GALT or SLS More Risky?

    Galectin Therapeutics has a beta of 0.689, which suggesting that the stock is 31.07% less volatile than S&P 500. In comparison SELLAS Life Sciences Group has a beta of 2.391, suggesting its more volatile than the S&P 500 by 139.11%.

  • Which is a Better Dividend Stock GALT or SLS?

    Galectin Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics pays -- of its earnings as a dividend. SELLAS Life Sciences Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GALT or SLS?

    Galectin Therapeutics quarterly revenues are --, which are smaller than SELLAS Life Sciences Group quarterly revenues of --. Galectin Therapeutics's net income of -$11.2M is lower than SELLAS Life Sciences Group's net income of -$7.1M. Notably, Galectin Therapeutics's price-to-earnings ratio is -- while SELLAS Life Sciences Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics is -- versus -- for SELLAS Life Sciences Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
    SLS
    SELLAS Life Sciences Group
    -- -- -- -$7.1M
  • Which has Higher Returns GALT or TCRT?

    Alaunos Therapeutics has a net margin of -- compared to Galectin Therapeutics's net margin of -28225%. Galectin Therapeutics's return on equity of -- beat Alaunos Therapeutics's return on equity of -189.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    GALT
    Galectin Therapeutics
    -- -$0.18 --
    TCRT
    Alaunos Therapeutics
    -- -$0.70 $3.8M
  • What do Analysts Say About GALT or TCRT?

    Galectin Therapeutics has a consensus price target of --, signalling upside risk potential of 967.96%. On the other hand Alaunos Therapeutics has an analysts' consensus of -- which suggests that it could grow by 10027.64%. Given that Alaunos Therapeutics has higher upside potential than Galectin Therapeutics, analysts believe Alaunos Therapeutics is more attractive than Galectin Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GALT
    Galectin Therapeutics
    0 0 0
    TCRT
    Alaunos Therapeutics
    0 0 0
  • Is GALT or TCRT More Risky?

    Galectin Therapeutics has a beta of 0.689, which suggesting that the stock is 31.07% less volatile than S&P 500. In comparison Alaunos Therapeutics has a beta of -0.444, suggesting its less volatile than the S&P 500 by 144.433%.

  • Which is a Better Dividend Stock GALT or TCRT?

    Galectin Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alaunos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galectin Therapeutics pays -- of its earnings as a dividend. Alaunos Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GALT or TCRT?

    Galectin Therapeutics quarterly revenues are --, which are smaller than Alaunos Therapeutics quarterly revenues of $4K. Galectin Therapeutics's net income of -$11.2M is lower than Alaunos Therapeutics's net income of -$1.1M. Notably, Galectin Therapeutics's price-to-earnings ratio is -- while Alaunos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galectin Therapeutics is -- versus -- for Alaunos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GALT
    Galectin Therapeutics
    -- -- -- -$11.2M
    TCRT
    Alaunos Therapeutics
    -- -- $4K -$1.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 3.65% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 4.9% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock